A research study to compare blood levels of cagrilintide after multiple doses of
different versions of cagrilintide in adults with overweight or obesity
Phase 4 – monitoring after market approval
Conditions:
obesity
Sponsor: Novo Nordisk A/S
trial.available_in:
БГ
Overview
Trial status: Authorised
Who can participate
Age group: 18-64 years
Gender: Female, Male
Target enrollment: 234 participants
БГ